Contemporary approach to the treatment of patients with the 2 and 3 genotype of hepatitis C
Contemporary approaches to the treatment of patients with the 2 and 3 genotype of hepatitis C were analyzed. The recommended duration of therapy for patients infected with HCV genotype 2 or 3 is 24 weeks. Extension of treatment with PegIFN alfa-2a/RBV from 24 to 48 weeks increased SVR24 rates in G2/3 patients who have detectable viraemia after 4 weeks of treatment, particularly those with advanced fi brosis.